Abstract 590P
Background
KRAS mutations are the most common molecular alteration in NSCLC, with the KRAS G12C variant reported in 12-13% of Western patients. We sought to determine the prevalence and characteristics of Australian pts with advanced NSCLC harbouring the KRAS G12C mutation.
Methods
We performed a multi-centre, retrospective review of pts diagnosed with advanced NSCLC in 2018 - 2019 for whom a KRAS result was available. Comprehensive clinicopathological and outcome data was collected and analysed for all KRAS G12C patients, and subsets of pts with non-G12C mutations (KRAS other) and KRAS wild type (KRAS WT).
Results
1085 pts from 17 sites were included, of whom 189 (17.4%) were KRAS G12C. Comprehensive data was collected on 163 KRAS G12C, 116 KRAS other and 104 KRAS WT pts. Baseline characteristics are summarised in the table. The 3 cohorts were similar in terms of age, sex, ECOG and metastatic disease at diagnosis. The KRAS G12C cohort had fewer never smokers (p <0.0001) and a trend to more PDL1 ≥50% patients (p=0.10) than the KRAS WT cohort. Comparable proportions in each cohort received any systemic therapy or any immunotherapy for advanced disease, with a similar number of lines of therapy delivered. Only 3 KRAS G12C patients received targeted therapy because of limited access. Median overall survival (mOS) in the KRAS G12Ccohort was 11.9 months (mo), compared to 17.0 mo in the KRAS other cohort (p=0.34), 26.8 mo in the KRAS WTcohort (p=0.02) and 17.6 mo in the KRAS WT cohort with EGFR/ALK/ROS1 mutated patients excluded (p=0.17). Table: 590P
KRAS G12C(n=163) | KRAS other (n=116) | KRAS WT(n=104) | All patients (n=383) | |
Age at diagnosis, years (range) | 66 (42-92) | 68 (41-89) | 69 (29-88) | 67 (29-92) |
Sex, n (%) | ||||
• Male | 84 (52) | 66 (57) | 61 (59) | 211 (55) |
• Female | 79 (48) | 50 (43) | 43 (41) | 172 (45) |
ECOG, n (%) | ||||
• 0-1 | 116 (71) | 81 (70) | 77 (74) | 274 (72) |
• 2+ | 23 (14) | 17 (15) | 9 (9) | 49 (13) |
• NA | 24 (15) | 18 (16) | 18 (17) | 60 (16) |
Smoking status, n (%) | ||||
• Current / past | 153 (94) | 107 (92) | 76 (73) | 336 (88) |
• Never | 3 (2) | 7 (6) | 21 (20) | 31 (8) |
• NA | 7 (4) | 2 (2) | 7 (7) | 16 (4) |
PDL1 result, n (%) | ||||
• <1% | 24 (15) | 17 (15) | 21 (20) | 62 (16) |
• 1-49% | 45 (28) | 42 (36) | 30 (29) | 117 (31) |
• ≥50% | 59 (36) | 39 (34) | 27 (26) | 125 (33) |
• Unknown | 35 (21) | 18 (16) | 26 (25) | 79 (21) |
Metastasis at diagnosis, n (%) | 137 (84) | 97 (84) | 86 (83) | 320 (84) |
Conclusions
Our study demonstrated a prevalence of KRAS G12C mutations of 17.4% among Australian pts with advanced NSCLC. The KRAS G12C, KRAS other and KRAS WT cohorts had similar patient and treatment patterns, although smoking history was more common in pts with a KRAS mutation. In the absence of other key driver mutations, there was no significant difference in mOS between cohorts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Walter and Eliza Hall Institute of Medical Research.
Funding
Amgen.
Disclosure
B. Markman: Financial Interests, Personal, Advisory Board: Amgen, Merck, Bristol Myers Squibb, BeiGene, AstraZeneca; Financial Interests, Institutional, Research Funding: Amgen. B. Solomon: Financial Interests, Institutional, Advisory Board: AstraZeneca, Novartis, Merck, Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Roche/Genentech; Financial Interests, Personal, Advisory Board: Amgen, Roche-Genentech, Eli Lilly, Takeda, Janssen; Financial Interests, Personal, Full or part-time Employment, Employed as a consultant Medical Oncologist at Peter MacCallum Cancer Centre: Peter MacCallum Cancer Centre; Financial Interests, Personal, Member of Board of Directors: Cancer Council of Victoria, Thoracic Oncology Group of Australasia; Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Institutional, Steering Committee Member, Principal Investigator and Steering committee Chair: Roche/Genentech, Pfizer; Financial Interests, Institutional, Steering Committee Member: Novartis. L.M. Nott: Financial Interests, Institutional, Research Funding: Roche, Servier; Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, Merck, Roche, Pfizer, MSD, Servier, Ipsen, AstraZeneca, Novartis; Financial Interests, Personal, Other, Honorarium: MSD, Amgen, Roche, Bristol Myers Squibb, Celgene. R. Roberts-Thomson: Financial Interests, Personal, Advisory Board: Bristol Myer Squibbb, Merck Sharpe and Dohme, Pfizer, AstraZeneca; Financial Interests, Personal, Invited Speaker: Bristol Myer Squibbb, Merck Sharpe and Dohme, Novartis, AstraZeneca, Pierre Fabre. B. Hughes: Financial Interests, Personal, Advisory Board: MSD, BMS, Pfizer, Roche, AstraZeneca, Takeda, Sanofi, Esai, Amgen; Financial Interests, Institutional, Research Funding: Amgen. N. Pavlakis: Financial Interests, Personal, Advisory Board: MSD, Merck, BMS, AstraZeneca, Takeda, Pfizer, Roche, Amgen, BeiGene; Financial Interests, Personal, Speaker, Consultant, Advisor: Merck, Pfizer, Roche, Takeda, Pierre-Faber, Illumina, Bayer; Financial Interests, Institutional, Research Funding: Bayer, Pfizer, Roche. S. Parakh: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Speaker, Consultant, Advisor: MSD, Roche, AstraZeneca; Financial Interests, Institutional, Research Funding: Bayer, Roche. D. Brungs: Financial Interests, Personal, Speaker, Consultant, Advisor: MSD. S.E. Bowyer: Financial Interests, Personal, Advisory Board: Lilly, Ipsen, Sanofi, MSD, Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, MSD, Sanofi. L. Warburton: Financial Interests, Personal, Advisory Board: Roche, Novartis, MSD, AstraZeneca, Bristol Myers Squibb. S.J. Harris: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb. S. Ramanujam: Financial Interests, Personal, Full or part-time Employment, Until April 2023: Amgen. A. Wang: Financial Interests, Personal, Full or part-time Employment: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract